
Russian Chemical Bulletin p. 682 - 688 (1995)
Update date:2022-08-11
Topics:
Pleshakov, V. G.
Akimov, V. M.
Nava, E. Huipe
Lindeman, S. V.
Struchkov, Yu. T.
et al.
Based on thermogravimetric characteristics first obtained for the model 6H-indeno<1,2-b>quinoline, the scheme of thermal conversions of this compound in the temperature range 20-700 deg C has been proposed, and the limit of its thermal stability (ca. 300 deg C) has been determined.This temperature is recommended as the optimum for synthesizing fused benzoaza(diaza)fluorenes.Based on the results of X-ray structural analysis, the molecules of the studied indenoquinoline form centrosymmetric pairs, which are arranged in (110) layers.The molecules are orientationally disordered self-association of these molecules is similar to the ?-? association of fused heterocyclic systems with ?-excessive and ?-deficient fragments.It has been suggested that interferon-inducing and antitumor compounds with an annelated indenyl fragment have a common mechanism of action according to the intercalation model of stacking structures. - Key words: CH-acids; 6H-indeno<1,2-b>quinoline, heterogeneous catalytic dehydrogenation, thermogravimetric and X-ray structural analysis; interferon-inducing and antitumor intercalators; topological factor; stacking structures.
View More
website:http://www.fwdchem.com
Contact:86-21-54450828
Address:Room 802,Lotus Tower ,159 Tianzhou Road,Xuhui District,Shanghai
Contact:+(852) 301-98033
Address:Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road, Wan Chai, Hong Kong
website:http://www.win-winchemical.com
Contact:0086-577-64498589
Address:6F, No. 396 Xingping Road, Longwan Industrial Zone, Wenzhou City, Zhejiang, 325000 P.R.China
Shaanxi HuaTai Bio-fine chemical company Ltd
Contact:86-029-87862197
Address:No. 5, 3rd Floor, 29 Yanta North Road, Beilin Dist.
Xiamen XM-Innovation Chemical Co., Ltd
Contact:+86-592-3216205
Address:Unit Q, 11/F, No.1 Office Building, Wuyuan Bay Business Center, Huli District, Xiamen City, Fujian Province, P.R.C
Doi:10.1016/j.tet.2005.06.120
(2005)Doi:10.1021/j100342a039
(1989)Doi:10.1007/s10600-005-0159-y
(2005)Doi:10.1016/j.ijpharm.2010.05.035
(2010)Doi:10.1007/BF00471245
()Doi:10.1021/j100380a004
(1990)